Adoptive immunotherapy against ovarian cancer
2016
The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop drug resistance and disease progression. New therapeutic strategies are needed to improve prognosis of patients with advanced EOC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
87
References
20
Citations
NaN
KQI